BIIB vs HRMY
BIIB: A pioneer in neuroscience and immunology, Biogen is a major biotechnology company focused on addressing high-unmet medical needs in complex diseases like Alzheimer’s, Multiple Sclerosis, and SMA. HRMY: Harmony Biosciences is a pharmaceutical company focused on delivering innovative therapies for rare neurological disorders, anchored by its commercial success in narcolepsy treatment.
Side-by-side fundamentals
| Metric | BIIB | HRMY | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $216.78 | $38.15 | |
| Market cap as of 2026-08-24 | $32.0B | $2.2B | |
| P/E as of 2026-08-24 | 37.20 | 12.45 | HRMY lower |
| PEG as of 2026-08-24 | 10.99 | n/a | |
| Net margin as of 2026-08-24 | +8.3% | +18.9% | HRMY higher |
| Gross margin as of 2026-08-24 | +74.0% | +75.4% | HRMY higher |
| Operating margin as of 2026-08-24 | +10.9% | +24.0% | HRMY higher |
| ROE as of 2026-08-24 | +4.5% | +20.1% | HRMY higher |
| ROA as of 2026-08-24 | +2.8% | +14.1% | HRMY higher |
| Debt / equity as of 2026-08-24 | 0.43 | 0.15 | HRMY lower |
| Revenue growth (YoY) as of 2026-08-24 | +0.3% | +24.3% | HRMY higher |
| Revenue CAGR (3y) SEC XBRL | -0.9% | +25.6% | HRMY higher |
| Beta as of 2026-08-24 | 0.09 | 1.01 | |
| 1-year return as of 2026-08-21 close | +55.8% | +2.3% | BIIB higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.